[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 14 of about 14
1. Yamada N, Okuse C, Nomoto M, Orita M, Katakura Y, Ishii T, Shinmyo T, Osada H, Maeda I, Yotsuyanagi H, Suzuki M, Itoh F: Obstructive jaundice caused by secondary pancreatic tumor from malignant solitary fibrous tumor of pleura: a case report. World J Gastroenterol; 2006 Aug 14;12(30):4922-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice caused by secondary pancreatic tumor from malignant solitary fibrous tumor of pleura: a case report.
  • A 77-year-old man on systemic chemotherapy against postoperative bilateral multiple lung metastases of malignant solitary fibrous tumor of the pleura suffered from pruritus and jaundice.
  • Abdominal computed tomography showed a tumor with peripheral enhancement in the pancreatic head, accompanied with the dilatation of intra- and extra-hepatic bile ducts.
  • He was diagnosed as having obstructive jaundice caused by a pancreatic head tumor.
  • The pancreatic head tumor was presumably diagnosed as the metastasis of malignant solitary fibrous tumor of the pleura, because the findings on the pancreatic head tumor on abdominal CT were similar to those on the primary lung lesion of malignant solitary fibrous tumor of the pleura.
  • The pancreatic tumor grew rapidly after the implantation of metallic stent in the inferior part of the common bile duct.
  • The patient died of lymphangitis carcinomatosa of the lungs.
  • Autopsy revealed a tumor that spread from the pancreatic head to the hepatic hilum.
  • Immunohistochemically the pancreatic head tumor cells were negative for staining of alpha-smooth muscle actin (alpha-SMA) or CD117, but positive for vimentin, CD34 and CD99.
  • These findings are consistent with those on malignant solitary fibrous tumor of the pleura.
  • We report the first case of obstructive jaundice caused by a secondary pancreatic tumor from malignant solitary fibrous tumor of the pleura.
  • [MeSH-major] Jaundice, Obstructive / etiology. Neoplasms, Fibrous Tissue / pathology. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / secondary. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2001 Sep;51(9):686-90 [11696171.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):538-43 [15086281.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):25-30 [10458214.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):297-9 [7075134.001]
  • [Cites] Ann Intern Med. 1985 Apr;102(4):487-90 [2983594.001]
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • (PMID = 16937484.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4087636
  •  go-up   go-down


2. De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M, Agostini M, de Braud F: Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol; 2008 Aug;3(8):938-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
  • Malignant solitary fibrous tumor (MSFT) of the pleura is a rare neoplasm, with unpredictable biologic behavior and a low sensitivity to chemotherapy.
  • To the authors' knowledge, no other effective medical treatment is available for this disease.
  • We report the first evidence of the activity of imatinib in a symptomatic patient with a chemo- and radio-resistant advanced MSFT, who obtained a 21-months lasting major clinical benefit with a consistent reduction in tumor metabolism.
  • Immunostaining of tumor cells demonstrated the positivity for PDGFR-alpha and PDGFR-beta and the absence of c-KIT over-expression, in the absence of c-KIT and PDGRFR mutations; all the cells strongly and diffusely expressed the ligand PDGF A in the cytoplasm.
  • This profile suggests that the observed tumor response was mediated through the inhibition of the tyrosine kinase activity of PDGFR.
  • Treatment with imatinib should be considered for patients with recurrent or unresectable MSFTs with PDGFR expression.
  • [MeSH-major] Piperazines / therapeutic use. Pleural Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Solitary Fibrous Tumor, Pleural / drug therapy
  • [MeSH-minor] Adult. Benzamides. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Pneumonectomy. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / metabolism. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670317.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


3. Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA: Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med; 2005 Jul;46(7):1201-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin is a glycoprotein that is overexpressed in several human tumors, including mesotheliomas and ovarian cancers, and has been identified as a potential target for therapy.
  • We evaluated the biodistribution and tumor-targeting ability of an antimesothelin tetravalent single-chain Fv-streptavidin fusion protein (SS1scFvSA) in mice.
  • To optimize the tumor uptake, the effect of the specific activity of 111In-DOTA-biotin was evaluated.
  • Decreasing the specific activity of DOTA-biotin by administering 0.1-5 microg of DOTA-biotin resulted in tumor uptake decreasing from 31.8 to 5.5 %ID/g (percentage injected dose per gram) at 2 h.
  • Pretargeted therapy of A431-K5 tumor with 90Y doses of 11.1-32.4 MBq resulted in a dose-dependent tumor response.
  • With 32.4 MBq, 86% of mice survived tumor free for 110 d.
  • All nontreated mice died, with a median survival of 16 d.
  • CONCLUSION: SS1scFvSA localized in the mesothelin-expressing tumor, resulting in a high accumulation of radiolabeled DOTA-biotin.
  • The specific activity of DOTA-biotin had a significant effect on its tumor uptake.
  • Therapeutic tumor doses were obtained without dose-limiting toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Iodine Radioisotopes / therapeutic use. Membrane Glycoproteins / metabolism. Radioimmunotherapy / methods. Radiopharmaceuticals / therapeutic use. Streptavidin / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Delivery Systems / methods. Female. GPI-Linked Proteins. Humans. Immunoglobulin Fragments / metabolism. Immunoglobulin Fragments / therapeutic use. Metabolic Clearance Rate. Mice. Mice, Nude. Organ Specificity. Recombinant Fusion Proteins / pharmacokinetics. Recombinant Fusion Proteins / therapeutic use. Survival Analysis. Tissue Distribution. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000290.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Immunoglobulin Fragments; 0 / Iodine Radioisotopes; 0 / Membrane Glycoproteins; 0 / Radiopharmaceuticals; 0 / Recombinant Fusion Proteins; 0 / mesothelin; 9013-20-1 / Streptavidin
  •  go-up   go-down


Advertisement
4. Gupta NP, Kumar R: Malignant gonadal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):363-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gonadal mesothelioma.
  • Malignant mesothelioma of the gonads is a rare and highly lethal disease.
  • Most of these tumors arise from the tunica vaginalis, which is a continuation of the mesothelium similar to the pleura and the peritoneum.
  • However, intratesticular and ovarian mesotheliomas have also been described.
  • Occasionally, patients with localized disease at the time of detection have been known to survive for more than 10 years; however, the majority will not live beyond 5 years, with median survival being approximately 23 months.
  • The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
  • Surgery forms the mainstay of management for all stages of the tumor.
  • Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
  • For the management of localized disease, we suggest the following protocol: initial staging of suspected cases with computed tomographic scan of the abdomen and pelvis; radical inguinal orchiectomy or hemiscrotectomy; retroperitoneal lymph node dissection in cases with positive nodes on scan or biopsy; and inguinal node dissection in cases requiring hemiscrotectomy.
  • For advanced or recurrent disease, we suggest local radical resection with chemotherapy, including high-dose cisplatin and doxorubicin for two cycles of 5 days each; add local radiotherapy for uncontrolled locally advanced disease.
  • [MeSH-major] Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Mesothelioma / drug therapy. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1475-8 [2146405.001]
  • [Cites] Minerva Urol Nefrol. 2000 Mar;52(1):33-5 [11517828.001]
  • [Cites] Surg Today. 1999;29(10):1106-10 [10554340.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Br J Radiol. 1999 May;72(857):502-4 [10505018.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Br J Urol. 1995 May;75(5):679-80 [7613813.001]
  • [Cites] Histopathology. 2000 Aug;37(2):150-9 [10931239.001]
  • [Cites] Jpn J Clin Oncol. 1991 Oct;21(5):377-83 [1753419.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):251-4 [10219022.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):19-24 [6197916.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):815-25 [7793480.001]
  • [Cites] Urol Int. 1995;55(4):215-7 [8588269.001]
  • (PMID = 12194801.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


5. Eren NT, Akar AR: Primary pericardial mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):369-73
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial mesothelioma.
  • Pericardial mesothelioma is a rare cancer for which treatment options are limited.
  • Operative intervention in pericardial mesothelioma is primarily for effusion control, for cytoreduction before multimodal therapy, or to deliver and monitor innovative intrapericardial therapies.
  • Early detection of the disease is the only hope for survival.
  • Failure of surgical techniques is usually associated with mesothelioma with entrapped heart, a large solid tumor mass, and a long history of pericardial effusion.
  • If the tumor is localized, resection is the only hope for this rare, but lethal, entity.
  • No single treatment modality is efficient by itself.
  • The exact role of intracavitary chemotherapy or irradiation remains to be defined.
  • Preliminary clinical application of photodynamic therapy and attempts at inhibiting the effects of growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, and vaccine treatments are being explored.
  • Adenoviral molecular chemotherapy recently completed phase I testing.
  • Clinical trials for pleural mesothelioma remain important as clinicians seek to improve the outcome for patients with pericardial mesothelioma.
  • In the future, combined therapeutic strategies involving radical surgery, radiotherapy, adjuvant chemotherapy, and immunomodulation may have a role in the treatment of pericardial mesotheliomas.
  • [MeSH-major] Heart Neoplasms / drug therapy. Heart Neoplasms / prevention & control. Heart Neoplasms / surgery. Mesothelioma / drug therapy. Mesothelioma / prevention & control. Mesothelioma / surgery. Pericardium / pathology
  • [MeSH-minor] Humans. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2001 Jun;42(3):425-7 [11398045.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):321-36 [9205997.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):695-700 [6668488.001]
  • [Cites] Ann Thorac Surg. 1967 Feb;3(2):162-5 [4951728.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Apr;114(4):817-21 [5026246.001]
  • [Cites] Pathol Int. 1999 Jul;49(7):658-62 [10504529.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Jpn Circ J. 2000 May;64(5):385-8 [10834456.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):167-72 [10395286.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Arch Pathol Lab Med. 1995 Mar;119(3):266-7 [7887781.001]
  • [Cites] Chest. 1980 Apr;77(4):559-61 [7357984.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):455S-460S [10619507.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2896-900 [11973650.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):875-7 [10810369.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1926-7 [10892948.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):81-5 [11243902.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1616-22 [9603146.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):77-81 [11836672.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):121-9 [11936818.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • (PMID = 12194802.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


6. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • It is characterized by atypical solid growth of mesothelium with formation of atypical cavities surrounded by fibrous stroma.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


7. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-major] Fibroma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D: Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol; 2002 Feb;29(1):51-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.
  • Peritoneal mesothelioma is a rare disease, but increasing in frequency.
  • The incidence is approximately one per 1,000,000 and about one fifth to one third of all mesotheliomas are peritoneal.
  • Because of its unusual nature, the disease has not been clearly defined either in terms of its natural history, diagnosis, or management.
  • Peritoneal mesothelioma patients generally present with two types of symptoms and signs; those with abdominal pain, usually localized and related to a dominant tumor mass with little or no ascites and those without abdominal pain, but with ascites and abdominal distention.
  • Prognosis as determined by clinical presentation, the completeness of cytoreduction, and gender (females survive longer than males) appears to be improved by the use of intraperitoneal chemotherapy.
  • Over the past decade, the management of these patients has evolved similarly to ovarian cancer treatment and now involves cytoreductive surgery, heated intraoperative intraperitoneal chemotherapy (HIIC) with cisplatin and doxorubicin, and early postoperative intraperitoneal paclitaxel.
  • These perioperative treatments are followed by adjuvant intraperitoneal paclitaxel and second-look cytoreduction.
  • Prolonged disease-free survival and reduced adverse symptoms with the current management strategy are documented by a high complete response rate as assessed by a negative second-look.
  • This multimodality treatment approach with cytoreductive surgery and intraperitoneal chemotherapy has resulted in a median survival of 50 to 60 months.
  • Peritoneal mesothelioma is an orphan disease that is treatable with expectations for "potential" cure in a small number of patients if diagnosed and treated early with definitive local/regional treatments.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by W.B. Saunders Company.
  • (PMID = 11836669.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Cardillo G, Carbone L, Carleo F, Masala N, Graziano P, Bray A, Martelli M: Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution. Ann Thorac Surg; 2009 Nov;88(5):1632-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution.
  • BACKGROUND: Solitary (localized) fibrous tumors of the pleura (SFTP) are rare slow-growing neoplasms that generally have a favorable prognosis.
  • METHODS: The records of 110 patients (63 men; mean age 56.4 years; range, 17 to 79) surgically treated for SFTP from July 1990 to February 2008, were evaluated for demographics, operative procedure, histopathology, morbidity, mortality, postoperative chemotherapy or radiotherapy, and long-term follow-up.
  • The main surgical approach was video-assisted thoracoscopic surgery (69 procedures with a conversion rate of 14.5%); 40 patients underwent thoracotomy and 1 had sternotomy.
  • The visceral pleura was the site of origin in 95 tumors, the parietal pleura in 13, the mediastinal pleura in 2 cases.
  • Sixty-three tumors were pedunculated, 35 were sessile, and 12 were inverted fibroma.
  • Tumors were pathologically benign in 95 cases (86.4%), and malignant in 15 (13.6%).
  • The overall disease-free survival rate was 90.8% (95.7% in benign cases and 67.1% in malignant cases; p < 0.05).
  • Eight patients presented with recurrence of disease, 4 cases of which were malignant and 4 were benign.
  • CONCLUSIONS: Solitary fibrous tumor of the pleura is a rare disease that includes both benign and malignant variants.The outcome is mostly benign, with an overall 10-year survival rate of 97.5%.
  • Pathologically benign lesions show a better disease-free survival rate than malignant lesions (95.7% versus 67.1%; p < 0.05).
  • Surgery is the gold standard of treatment as neither radiotherapy nor chemotherapy proved to be effective.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853123.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Cagol PP, Pasqual E, Bacchetti S: Natural history of the neoplastic locoregional disease: clinical and pathological patterns. J Exp Clin Cancer Res; 2003 Dec;22(4 Suppl):1-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of the neoplastic locoregional disease: clinical and pathological patterns.
  • A great number of locoregional treatments are currently carried out to treat a variety of locoregional neoplastic diseases.
  • Indications are the treatment of primary and metastatic liver tumors, peritoneal mesotheliomas, peritoneal spread of ovarian carcinomas, peritoneal recurrences of gastrointestinal cancers, peritoneal spread of retroperitoneal sarcomas, melanomas and sarcomas of the limbs, some primary tumors of the brain, breast, kidney, lung, bladder.
  • But to deal with locoregional therapy demands to clarify some features of these malignancies.
  • At this regard, the knowing of their natural history can be crucial to guide the choice of the correct locoregional treatment.
  • For instance peritoneal carcinomatosis is considered as a main step of disease progression for ovarian cancer and often for gastrointestinal tumors as well.
  • However when the tumors are confined on the surface of the peritoneum, basing on their own natural history, they can be considered as localized diseases.
  • Selected patients with peritoneal neoplastic seeding, previously considered in a preterminal condition, can be considered as candidates for curative treatment, using cytoreductive surgical tecniques (16) and hyperthermic intraperitoneal chemotherapy (19).
  • In this paper the main aspects of liver metastases and peritoneal carcinomatosis natural history, two of the most frequently recognized indications for locoregional therapy, are presented.
  • [MeSH-minor] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767897.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 20
  •  go-up   go-down


11. Saynak M, Bayir-Angin G, Kocak Z, Oz-Puyan F, Hayar M, Cosar-Alas R, Karamustafaoglu A, Yurut-Caloglu V, Caloglu M, Yoruk Y: Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy. Med Oncol; 2010 Mar;27(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy.
  • Solitary fibrous tumor (SFT) of the pleura is an uncommon neoplasm with non-specific symptoms and non-pathognomonical radiological findings.
  • Surgery allows establishment of a definitive diagnosis as well as a cure of the disease.
  • The role of radiotherapy or chemotherapy in the management of the disease is unclear because of the rarity of the disease and the successful results of the surgical treatment.
  • Long-term clinical follow-up may be useful for the patients with SFT because of the potential adverse biological behavior of this tumor, which may lead to repeated recurrences and/or malignant transformation.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Solitary Fibrous Tumor, Pleural / radiotherapy
  • [MeSH-minor] Aged. Dyspnea / etiology. Female. Humans. Immunohistochemistry. Palliative Care. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):117-21 [18404798.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Dtsch Med Wochenschr. 2001 Jan 5;126(1-2):12-5 [11200659.001]
  • [Cites] Pathol Int. 2007 Apr;57(4):213-8 [17316417.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • (PMID = 19165637.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Morán-Mendoza A, Alvarado-Luna G, Calderillo-Ruiz G, Serrano-Olvera A, López-Graniel CM, Gallardo-Rincón D: Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:315-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meigs' syndrome is the association of ovarian fibroma, pleural effusion, and ascites.
  • The patient was a 46-year-old woman with right pleural effusion, ascites, ovarian tumor, and CA125 level of 1808 U/mL.
  • Tomography revealed ascites and bilobate pelvic tumor of approximately 25 cm.
  • The diagnosis of advanced epithelial ovarian cancer was considered, and the patient was treated with chemotherapy.
  • Three chemotherapy schemes were applied due to the total lack of response in tumor volume; however, CA125 decreased to 90 U/mL.
  • Thus, surgery was performed with resection of 25 cm of the left ovarian tumor, with intact capsule and without implants; the result of histopathologic analysis was fibroma.
  • Although the association between ovarian tumor, pleural effusion, ascites, and marked elevation of CA125 is highly indicative of epithelial ovarian cancer, Meigs' syndrome must be considered in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Meigs Syndrome / therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515612.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Number-of-references] 27
  •  go-up   go-down


13. Prunotto M, Bosco M, Daniele L, Macri' L, Bonello L, Schirosi L, Rossi G, Filosso P, Mussa B, Sapino A: Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer; 2009 May;64(2):244-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
  • We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT).
  • SFT-derived cells were treated with imatinib at different time points.
  • Western blotting for PDGFR-beta, phospho-PDGFR-beta or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib.
  • Western blotting showed that PDGFR-beta was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-beta phosphorylation and SMA expression.
  • With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Piperazines / pharmacology. Pyrimidines / pharmacology. Receptor, Platelet-Derived Growth Factor beta / drug effects. Solitary Fibrous Tumor, Pleural / metabolism
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Blotting, Western. Cells, Cultured. Cisplatin / administration & dosage. Female. Fluorescent Antibody Technique. Fluorouracil / administration & dosage. Humans. Imatinib Mesylate. In Vitro Techniques. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Pneumonectomy. Radiotherapy. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041155.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • In more chronic cases, paucicellular fibrosis with a foreign body giant cell reaction is noted.
  • The talc is polarizable and deposited in linear fashion within the tumour.
  • Tumour nodules developing subjacent to iatrogenic wound sites were noted in 8/48 (17%) cases.
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • In 2/8 (25%) cases the locally irradiated tumour showed prominent bizarre multinucleated tumour giant cells and intense mixed inflammation, a feature not seen in the background (non-irradiated) tumour.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down






Advertisement